Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

TY - JOUR

T1 - Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

AU - Nussenblatt, Robert B.

AU - Thompson, Darby J S

AU - Li, Zhuqing

AU - Peterson, Jan S.

AU - Robinson, Randy R.

AU - Shames, Richard S.

AU - Nagarajan, Sudha

AU - Tang, Meina Tao

AU - Mailman, Michelle

AU - Velez, Gisela

AU - Roy, Chandra

AU - Levy-Clarke, Grace A.

AU - Suhler, Eric B.

AU - Djalilian, Ali R.

AU - Sen, Hatice Nida

AU - Al-Khatib, Shadi

AU - Ursea, Roxana

AU - Srivastava, Sunil

AU - Bamji, Allison

AU - Mellow, Susan

AU - Sran, Pushpa

AU - Waldmann, Thomas A.

AU - Buggage, Ronald R.

N1 - Therapy for severe uveitis is frequently long-term immunosuppression using systemic corticosteroids and cytotoxic agents, but side effects make long-term therapy difficult. A long-term (>4 year) Phase I/II single armed interventional study using intravenous anti-IL-2 receptor alpha treatments (daclizumab) and a short-term Phase II study evaluating the use of a subcutaneous daclizumab formulation were conducted.

PY - 2003/11/1

Y1 - 2003/11/1

UR - https://ohsu.pure.elsevier.com/en/publications/humanized-anti-interleukin-2-il-2-receptor-alpha-therapy-long-ter-2

U2 - 10.1016/S0896-8411(03)00113-6

DO - 10.1016/S0896-8411(03)00113-6

M3 - Article

VL - 21

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

IS - 3

ER -